Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1 protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the complete metabolic response (CMR) rate and safety of pembrolizumab monotherapy in newly diagnosed cHL, we conduct...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Allen, Pamela B., Savas, Hatice, Evens, Andrew M., Advani, Ranjana H., Palmer, Brett, Pro, Barbara, Karmali, Reem, Mou, Eric, Bearden, Jeffrey, Dillehay, Gary, Bayer, Robert A., Eisner, Robert M., Chmiel, Joan S., O’Shea, Kaitlyn, Gordon, Leo I., Winter, Jane N.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2021
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955404/
https://ncbi.nlm.nih.gov/pubmed/32992341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007400
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge